Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

ConditionsCutaneous T Cell Lymphoma Cutaneous T-Cell Lymphoma/Mycosis Fungoides Cutaneous T-Cell Lymphoma/Sezary Syndrome

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorFondazione Italiana Linfomi - ETS

About this trial

The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.

Eligibility criteria

Qualifiers

Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1.

Age ≥18 years.

Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023.

Availability of complete medical records in order to provide protocol required variables

Disqualifiers

Patients not meeting the above-mentioned inclusion criteria.

Refuse to sign a written informed consent.

Trial design

Treatments tested in this trial

Not listed

Trial groups

400 Participants

are grouped into 1 trial group

Locations

AOU Ospedali Riuniti delle Marche - Clinica di Ematologia Ancona Italy

IRCCS Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia Bari Italy

U.O.C. Dermatologia e Venereologia Universitaria - A.O.U. Policlinico Consorziale Bari Italy

Policlinico S.Orsola-Malpighi - Istituto di Ematologia Bologna Italy

Sponsors and collaborators

Fondazione Italiana Linfomi - ETS

Lead sponsor

Takeda

Collaborator

Source ClinicalTrials.gov